Canada markets closed

Moderna, Inc. (MRNA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
150.00-8.00 (-5.06%)
At close: 04:00PM EDT
150.12 +0.12 (+0.08%)
After hours: 06:52PM EDT

Moderna, Inc.

200 Technology Square
Cambridge, MA 02139
United States
617 714 6500
https://www.modernatx.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees3,400

Key Executives

NameTitlePayExercisedYear Born
Dr. Noubar B. Afeyan Ph.D.Co-Founder, Independent Non Exec. Chairman & Member of Technology Advisory Board1.12MN/A1963
Mr. Stephane BancelCEO & Director3.16MN/A1973
Dr. Stephen Hoge M.D.Pres1.8M165.87M1976
Mr. David W. MelineChief Financial Officer1.24MN/A1957
Ms. Shannon Thyme KlingerChief Legal Officer & Corp. Sec.1.76MN/A1971
Mr. Juan AndresChief Technical Operations & Quality Officer1.6M194.29M1965
Dr. John V. W. Reynders Ph.D.Chief Information OfficerN/AN/AN/A
Dr. Melissa J. Moore Ph.D.Chief Scientific Officer & Member of Scientific Advisory BoardN/AN/AN/A
Ms. Lavina Talukdar CFASr. VP & Head of Investor RelationsN/AN/AN/A
Colleen HusseySr. Director of Corp. CommunicationsN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Moderna, Inc.’s ISS Governance QualityScore as of July 31, 2022 is 10. The pillar scores are Audit: 8; Board: 10; Shareholder Rights: 10; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.